If you have been reading about Synaptogenesis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-20. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical lyophilized research form. |
| Solubility | Soluble in DMSO; limited in water | Depends on purity and salt form. |
| Storage temperature | -20 °C or lower | Desiccated and protected from light. |
| Analytical method | RP-HPLC and LC-MS | Common for purity and identity. |
| Regulatory status | Research chemical in many countries | Not widely approved as a medicine. |
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
Seizures Haemorrhage † Myelosuppression, including: thrombocytopenia, anaemia, neutropenia and lymphopenia, in descending order of frequency. Omacetaxine mepesuccinate can cause fetal harm when administered to a pregnant woman. Women using HHT should avoid becoming pregnant and also avoid nursing while receiving HHT.
Crick began to think of a solution to this problem in the line of Watson's idea that the role of RNA was overlooked. He rejected Gamow's assumption that molecules like amino acids that are too different chemically from nucleic acid that it would be structurally impossible to bind to DNA. Instead, he visualised a certain kind but unknown molecule that linked nucleic acids and carry amino acids to ribosomes to form peptide chains. As he discussed it with his colleague Sydney Brenner about the features of such molecule, Brenner was impressed with the idea and named the concept as the "adaptor hypothesis". The adaptor was then a hypothetical molecule that apparently help in an indirect interaction between DNA, RNA and amino acids during protein synthesis. As Crick explained:I don't think that anybody looking at DNA or RNA would think of them as templates for amino acids were it not for other, indirect evidence... [In one possible scheme] each amino acid would combine chemically, at a special enzyme, with a small molecule which, having a specific hydrogen-bonding surface, would combine specifically with the nucleic acid template, This combination would also supply the energy necessary for polymerisation. In its simplest form there would be 20 different kinds of adaptor molecule, one for each amino acid, and 20 different enzymes to join the amino acid to their adaptors, Sydney Brenner, with whom I have discussed this idea, calls this the "adaptor hypothesis", since each amino acid is fitted with an adaptor to go on to the template...
One of the most common erroneous explanations of aerodynamic lift asserts that the air must traverse the upper and lower surfaces of a wing in the same amount of time. This implies that since the upper surface presents a longer path the air must be moving over the top of the wing faster than over the bottom. Bernoulli's principle is then cited to conclude that the pressure on top of the wing must be lower than on the bottom. This explanation is incorrect because there is no physical principle that requires equal transit time around solid bodies. Theory predicts – and experiments confirm – that for a body experiencing lift the air traverses the top surface of in a shorter time than it traverses the bottom surface. While the equal-time explanation is false, it is not the Bernoulli principle that is false, because this principle is well established; Bernoulli's equation is used correctly in common mathematical treatments of aerodynamic lift.
== Associated disease states and abnormalities == Abnormal GnSAF bioactivity has been associated with premature surges in LH and LH hypersecretion. Optimal and timely changes in serum LH concentrations are crucial to ensuring the viability of oocytes and implantation after fertilization. For successful implantation of a zygote, the mid-cycle LH surge after the decline of GnSAF and ovulation must correspond with uterine receptivity. Hypersecretion of LH contributes to cycle disturbance, infertility and increased chances of miscarriage. GnSAF has been implicated in polycystic ovary syndrome (PCOS), one of the most common ovarian disorders responsible for causing anovulatory infertility. Approximately 40% of women with PCOS display higher GnRH pulse frequency and tonic hypersecretion of LH due to hypersecretion of androgens from the polycystic ovary. Androgens are readily metabolized to estradiol in the ovaries. The supraphysiological concentrations of estradiol maintains high pituitary responsiveness to GnRH, permitting the hypersecretion of LH. Superovulation is common in women who take medications such as clomiphene citrate, an anti-estrogenic oral medication used to treat infertility. Superovulation is induced in women to increase chances of fertilization and conception in assisted reproductive techniques. In naturally superovulating women, the mid-cycle LH surge is significantly lower compared to that of normal ovulating women due to the presence of GnSAF in the late follicular phase fluid.
Since the ligand is responsible for cellular interaction, it is chosen for the application depending on the target site. The target site contains binding sites that the ligand targets to deliver the LTL to the desired area. Favorable target site characteristics are determined by what is commonly expressed by tissues of the pathology of interest. Determinants can include histones, basement membrane fibrinogen, selectins, adhesion molecules, and other ligand targets. For example, in some human cancer tumors such as ovarian carcinomas, folate is over-expressed. LTLs for targeting cancer often use a ligand that targets this over-expression of folate to localize drug delivery to the desired area. The tumor microenvironment of solid tumor cancers is also a unique targeting site. Tumor endothelial cells are important for angiogenesis, which is key to tumor growth; therefore, using LTLs to target these cells can limit the growth and vascularization of a tumor.
Sources: en.wikipedia.org
Nicholson at Birkbeck College, University of London and later at Imperial College London. In 1984, Nicholson showed 1H NMR spectroscopy could potentially be used to diagnose diabetes mellitus, and later pioneered the application of pattern recognition methods to NMR spectroscopic data. In 1994 and 1996, liquid chromatography mass spectrometry metabolomics experiments were performed by Gary Siuzdak while working with Richard Lerner (then president of the Scripps Research Institute) and Benjamin Cravatt, to analyze the cerebral spinal fluid from sleep deprived animals. One molecule of particular interest, oleamide, was observed and later shown to have sleep inducing properties. This work is one of the earliest such experiments combining liquid chromatography and mass spectrometry in metabolomics. In 2005, the first metabolomics tandem mass spectrometry database, METLIN, for characterizing human metabolites was developed in the Siuzdak laboratory at the Scripps Research Institute. METLIN has since grown and as of 2025, METLIN contains MS/MS experimental data on over 960,000 molecular standards and other chemical entities, each compound having experimental tandem mass spectrometry data generated from molecular standards at multiple collision energies and in positive and negative ionization modes. METLIN is the largest repository of tandem mass spectrometry data of its kind. The dedicated academic journal Metabolomics first appeared in 2005, founded by its current editor-in-chief Roy Goodacre.
== Measurement of renal clearance == Renal clearance can be measured with a timed collection of urine and an analysis of its composition with the aid of the following equation (which follows directly from the derivation of (10b)):
Enobosarm is a nonsteroidal SARM, acting as an agonist of the androgen receptor (AR), the biological target of androgens and anabolic steroids like testosterone and dihydrotestosterone (DHT). However, it shows dissociation of effect between tissues in preclinical studies, with agonistic and anabolic effects in muscle and bone, agonistic effects in breast, and partially agonistic or antagonistic effects in the prostate gland and seminal vesicles. The AR-mediated effects of enobosarm in many other androgen-sensitive tissues are unknown. Enobosarm was first identified in 2004 and has been under clinical development since at least 2005. It is the most well-studied SARM of all of the agents that have been developed. According to GTx, its developer, a total of 25 clinical studies have been carried out on more than 1,700 people involving doses from 1 to 100 mg as of 2020. However, enobosarm has not yet completed clinical development or been approved for any use. As of November 2023, it is in phase 3 clinical trials for the treatment of breast cancer and is in phase 2 studies for improvement of body composition in people taking GLP-1 receptor agonists. Enobosarm was developed by GTx, Inc., and is now being developed by Veru, Inc. Aside from its development as a potential pharmaceutical drug, enobosarm is on the World Anti-Doping Agency list of prohibited substances and is sold for physique- and performance-enhancing purposes by black-market Internet suppliers. In one survey, 2.7% of young male gym users reported using SARMs.
It is very important not to treat people with thalassemia with an iron supplement, as this can lead to hemochromatosis. A hemoglobin electrophoresis provides useful evidence for distinguishing these two conditions, along with iron studies.
A man is arrested on suspicion of attempted murder after four people were injured when they were hit by a car being driven on the wrong side of the road in Shaftesbury Avenue, central London. King Charles III delivers the Royal Christmas Message from London's Fitzrovia Chapel, where he praises health workers and calls for unity following the summer riots. Archbishop of York Stephen Cottrell delivers a Christmas message in place of the Archbishop of Canterbury, doing so as he prepares to assume acting charge of the Church of England. 26 December – Data collected by MRI Software indicates a 4% decrease in the number of Boxing Day shoppers compared to the same day in 2023. 27 December The Prime Minister pays tribute to Nick Starmer, his younger brother who died from cancer the previous day. Conservative leader Kemi Badenoch expresses her condolences. Flights to and from some of the UK's major airports, including Gatwick and Manchester, are disrupted due to fog. Former Conservative Justice Secretary David Gauke, who is leading a review into sentencing and prison overcrowding, calls for greater use of open prisons in order to ease the pressure on closed category prisons. A man is charged with four counts of attempted murder and remanded in custody over an incident involving a car in London on Christmas Day. 28 December – Fog continues to disrupt flights at UK airports. 29 December Weather warnings for rain, snow, and winds of up to 70 mph are issued for parts of the UK on New Year's Eve and New Year's Day.
Sources: en.wikipedia.org
== Traditional medicine == Andean indigenous peoples use the tea in traditional medicine practices. Visitors to the city of Cuzco in Peru, and La Paz in Bolivia are greeted with the offering of coca leaf infusions (prepared in teapots with whole coca leaves) purportedly to help the newly arrived traveler overcome the malaise of high altitude sickness. Coca tea may be recommended for travelers in the Andes to prevent altitude sickness, although its actual effectiveness has never been systematically studied.
=== Legal history === In October 2001, the US Department of Justice, states attorneys general, and TAP Pharmaceutical Products, a subsidiary of Abbott Laboratories, settled criminal and civil charges against TAP related to federal and state medicare fraud and illegal marketing of the drug leuprorelin. TAP paid a total of $875 million, which was a record high at the time. The $875 million settlement broke down to $290 million for violating the Prescription Drug Marketing Act, $559.5 million to settle federal fraud charges for overcharging Medicare, and $25.5 million reimbursement to 50 states and Washington, D.C., for filing false claims with the states' Medicaid programs. The case arose under the False Claims Act with claims filed by Douglas Durand, a former TAP vice president of sales, and Joseph Gerstein, a doctor at Tufts University's HMO practice. Durand, Gerstein, and Tufts shared $95 million of the settlement. There have since been various suits concerning leuprorelin use, none successful. They either concern the oversubscription of the drug or undue warning about the side effects. Between 2010 and 2013, the FDA updated the Lupron drug label to include new safety information on the risk of thromboembolism, loss of bone density and convulsions. The FDA then asserted that the benefits of leuprorelin outweigh its risks when used according to its approved labeling. Since 2017, the FDA has been evaluating leuprorelin's connection to pain and discomfort in musculoskeletal and connective tissue.
These results indicate that in mice: a) α-ketoglutarate stimulates kidney OXGR1 to activate pendrin-mediated reabsorption of sodium and chloride by type B and non-A–non-B intercalated cells; b) high alkaline (i.e., sodium bicarbonate) intake produces significant increases in urine pH and α-ketoglutarate levels and impairs secretion of bicarbonate into the CDS tubules' lumens; c) the acid–base balance (i.e., levels of acids relative to their bases) in the face of high alkali intake depends on the activation of OXGR1 by α-ketoglutarate; d) alkaline loading directly or indirectly stimulates α-ketoglutarate secretion into the kidney's proximal tubules where further down these tubules it activates OXGR1 and thereby the absorption and secretion of various agents that contribute to restoring a physiologically normal acid-base balance; and e) α-ketoglutarate stimulates OXGR1-bearing CDS cells to raise their levels of cytosolic Ca2+) and in diabetic mice (and presumably other conditions involving high levels of blood and/or urine glucose) to increase these cells uptake of Na+.
=== The long-standing exclusive focus on women's reproductive health === For centuries, medical focus on women has largely centered on reproductive health, with limited attention to other medical needs.
Sources: en.wikipedia.org
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.
Mass spectrometry is commonly used to confirm molecular mass, while RP-HPLC estimates purity. These methods can be combined with amino acid analysis or NMR for further structural confirmation. A certificate of analysis alone does not guarantee independent verification.
Legality depends on the country and the intended use. In many places it is not approved as a drug and may be regulated as a research chemical. Buyers should check local laws and institutional policies before obtaining it.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.